Milestone Scientific Reports Q2 2026 Financial Results with Improved Sales and Reduced Losses

Milestone Scientific Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $1.06 million, a decrease from a loss of $1.48 million in the same period last year. The company generated $2.84 million in product sales, a 22.3% increase from $2.32 million in the prior year. This growth was primarily driven by a 19.3% rise in dental product sales, which reached approximately $2.73 million, and a significant increase in medical product sales, which rose to $106,400 from $32,100, reflecting a 231.5% increase. The gross profit for the quarter was $1.91 million, up from $1.62 million, although the gross margin decreased slightly to 67.2% from 69.6% due to increased product costs.

For the six months ending June 30, 2026, Milestone Scientific reported total product sales of $5.00 million, a 9.8% increase from $4.56 million in the same period of 2025. Dental revenue accounted for the majority of this growth, increasing by 7.1% to $4.79 million, while medical revenue surged by 156.7% to $214,000. The company’s total gross profit for the first half of 2026 was $3.47 million, compared to $3.27 million in the previous year, although the gross margin also saw a decline to 69.4% from 71.7%.

Milestone Scientific's operational expenses decreased significantly, with total selling, general, and administrative expenses dropping to $5.32 million for the first half of 2026, down from $6.29 million in the prior year. This reduction was attributed to lower consulting fees, research and development costs, and quality control expenses. The company’s loss from operations improved to $1.89 million for the first half of 2026, compared to a loss of $3.48 million in the same period of 2025, indicating a positive trend in operational efficiency.

In terms of strategic developments, Milestone Scientific completed a private placement on April 20, 2026, raising approximately $1.81 million, which has bolstered its liquidity position. The company also reported a significant increase in its cash and cash equivalents, which rose to $2.07 million as of June 30, 2026, compared to $1.11 million at the end of 2025. However, the company continues to face challenges, including an accumulated deficit of $135.67 million and ongoing operating losses, raising concerns about its ability to continue as a going concern.

Looking ahead, Milestone Scientific aims to expand the adoption of its Dynamic Pressure Sensing Technology® platform and enhance the commercialization of its medical segment. The company is focused on managing operating expenses while pursuing growth initiatives, although it acknowledges the need for additional financing to support its operations. The recent receipt of a technology-specific CPT code for its CompuFlo Epidural System is expected to facilitate increased adoption in anesthesia pain management clinics, potentially accelerating revenue growth in the medical segment.